New publication: Validating a bespoke 96-well plate for high-throughput drug susceptibility testing of M. tuberculosis Philip Fowler, 28th August 201829th September 2018 0 shares This paper, published in Antimicrobial Agents and Chemotherapy, determines the reproducibility and accuracy of minimum inhibitory concentrations for a panel of 14 different anti-TB compounds using a specifically designed 96-well plate (called UKMYC5) manufactured by Thermo Fisher. Since the UKMYC5 plate is being used by the CRyPTIC consortium to measure the drug susceptibility profiles of >30,000 clinical TB samples collected worldwide between now and 2020, this manuscript lays the foundations for this large and ambitious tuberculosis research project. It is free to read and download, and the paper briefly mentions my AMyGDA software which we will be using as an independent measuring technique to quality control the measurements made by the laboratory scientists. You can download and AMyGDA software from here. A manuscript is currently under review – you can read a preprint here. The bacterial growth on the UKMYC5 plates are also being classified by a Citizen Science project I have setup, BashTheBug. Share this:Twitter Related antimicrobial resistance clinical microbiology publication tuberculosis
antimicrobial resistance New preprint: Predicting pyrazinamide resistance by machine learning 29th April 201929th April 2019 Usually, the protein that an antibiotic binds is essential for bacterial survival, which is how… Share this:Twitter Read More
New publication: WHO catalogue of Mycobacterium tuberculosis resistant mutations 28th March 202228th March 2022 The CRyPTIC project collecting over 20,000 clinical samples of TB and for each, sequencing its… Share this:Twitter Read More
tuberculosis Numpy v Biopython 25th July 20194th August 2019 Having only recently having to write bioinformatics Python code that e.g. interrogate GenBank files to… Share this:Twitter Read More